GlassScriptPhysician profile
Surendra K Sirpal
NPI 1023038494
$4,703.25
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $1,491 · 2021: $838 · 2022: $152 · 2024: $53.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $621.71 | 2019-2022 | |
| Amgen INC. | $348.37 | 2019-2021 | |
| Seagen INC. | $294.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $264.98 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $255.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.25 | 2019-2024 | |
| Celgene Corporation | $190.69 | 2019-2020 | |
| Astellas Pharma US INC | $177.22 | 2020-2022 | |
| Incyte Corporation | $157.30 | 2019-2020 | |
| Lilly USA, LLC | $153.95 | 2019-2021 | |
| Dova Pharmaceuticals | $139.89 | 2019-2020 | |
| Daiichi Sankyo INC. | $136.72 | 2019-2021 | |
| Genzyme Corporation | $131.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $122.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.84 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Sirpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.